Correlation Between Iridium Communications and Tscan Therapeutics
Can any of the company-specific risk be diversified away by investing in both Iridium Communications and Tscan Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Iridium Communications and Tscan Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Iridium Communications and Tscan Therapeutics, you can compare the effects of market volatilities on Iridium Communications and Tscan Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Iridium Communications with a short position of Tscan Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Iridium Communications and Tscan Therapeutics.
Diversification Opportunities for Iridium Communications and Tscan Therapeutics
-0.22 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Iridium and Tscan is -0.22. Overlapping area represents the amount of risk that can be diversified away by holding Iridium Communications and Tscan Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Tscan Therapeutics and Iridium Communications is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Iridium Communications are associated (or correlated) with Tscan Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Tscan Therapeutics has no effect on the direction of Iridium Communications i.e., Iridium Communications and Tscan Therapeutics go up and down completely randomly.
Pair Corralation between Iridium Communications and Tscan Therapeutics
Given the investment horizon of 90 days Iridium Communications is expected to generate 0.78 times more return on investment than Tscan Therapeutics. However, Iridium Communications is 1.29 times less risky than Tscan Therapeutics. It trades about 0.06 of its potential returns per unit of risk. Tscan Therapeutics is currently generating about -0.03 per unit of risk. If you would invest 2,709 in Iridium Communications on September 3, 2024 and sell it today you would earn a total of 263.00 from holding Iridium Communications or generate 9.71% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Iridium Communications vs. Tscan Therapeutics
Performance |
| Timeline |
| Iridium Communications |
| Tscan Therapeutics |
Iridium Communications and Tscan Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Iridium Communications and Tscan Therapeutics
The main advantage of trading using opposite Iridium Communications and Tscan Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Iridium Communications position performs unexpectedly, Tscan Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tscan Therapeutics will offset losses from the drop in Tscan Therapeutics' long position.| Iridium Communications vs. IHS Holding | Iridium Communications vs. Cogent Communications Group | Iridium Communications vs. IDT Corporation | Iridium Communications vs. Cable One |
| Tscan Therapeutics vs. DiaMedica Therapeutics | Tscan Therapeutics vs. Lyra Therapeutics | Tscan Therapeutics vs. Centessa Pharmaceuticals PLC |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Other Complementary Tools
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |